Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00151385
Status:
WITHDRAWN
Last Update Posted:
2012-06-28
First Post:
2005-09-06
Brief Title:
Study Evaluating Inhibitor Specificity in Hemophilia A
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Multicenter Study to Describe the Immunogenic Epitopes of Factor VIII in Previously Treated Patients With Congenital Hemophilia A Who Develop De Novo Factor VIII Inhibitors While Receiving Factor VIII Infusion Therapy
Status:
WITHDRAWN
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This investigation will utilize a systematic determination of anti-FVIII antibody specificity in PTPs 50 ED with hemophilia A who have developed inhibitors in response to treatment with any FVIII products A group of patients with hemophilia A who have no evidence of current or prior FVIII inhibitor will be included for comparison The objective of this study is to describe the patterns of antibodies and associated epitopes in the study population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None